Fennec Pharmaceuticals (TSE:FRX)
NASDAQ:FRX
FRX Stock Chart & Stats
C$9.04
C$0.03(0.34%)
At close: 4:00 PM EST
C$9.04
C$0.03(0.34%)
Day’s Range― - ―
52-Week RangeC$7.05 - C$13.83
Previous CloseN/A
Volume1.30K
Average Volume (3M)481.00
Market Cap
C$311.66M
Enterprise ValueC$146.19M
Total Cash (Recent Filing)C$36.72M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 19, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding34,475,178
10 Day Avg. Volume402
30 Day Avg. Volume481
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)6.29
Price to Sales (P/S)4.86
P/FCF Ratio-15.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$20.73Price Target Upside129.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.25
Revenue Forecast (FY)C$99.86M
Bulls Say, Bears Say
Bulls Say
Clinical Guideline Endorsement And Real‑world EvidenceInclusion of PEDMARK in prominent clinical guidelines alongside ongoing investigator‑sponsored and real‑world studies could strengthen clinical credibility and encourage wider clinician adoption.
Commercial Adoption ExpansionAnalysts observe accelerating uptake of PEDMARK among adolescent and young adult patients across multiple tumor types, indicating rising commercial demand beyond the pediatric population.
Profitability And Commercial ModelAnalyst expects the company may have reached profitability and to sustain it, supported by a lean commercial model, anticipated royalty receipts in Europe, and reduced interest expenses following debt redemption.
Bears Say
Partnership, Competition And IP UncertaintyUncertainties around partner relationships, potential competitive threats, and questions about intellectual property protection could undermine market share and long‑term commercial prospects.
Regulatory Approval RiskKey risks include failure to obtain approvals in additional territories, which could limit market access and constrain international revenue growth.
Sales And Uptake ShortfallAnalyst notes reported sales were below forecasts and warns that slower U.S. commercial uptake could delay profitability and weaken revenue momentum.
Fennec Pharmaceuticals News
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$7.05 and its highest was C$13.83 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is C$311.66M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is May 19, 2026 which is in 38 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Mar 24, 2026. The company reported -C$0.234 earnings per share for the quarter, missing the consensus estimate of C$0.058 by -C$0.292.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,475,178 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -C$0.234 in its last earnings report, missing expectations of C$0.058. Following the earnings report the stock price went down -18.621%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$20.73 (129.32% Upside)
C$20.73 (129.32% Upside)
Blogger Sentiment
Bullish
TSE:FRX Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.48%
12-Months-Change
Fundamentals
Return on Equity
-236.42%
Trailing 12-Months
Asset Growth
57.03%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FRX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted substantial commercial momentum (FY sales +50%, Q4 sales +75%), strengthened balance sheet through a $42M capital raise and full debt redemption, a favorable patent settlement extending exclusivity to 2033, and strong progress on clinical evidence and international rollout (Norgine). These positives were balanced by meaningful increases in operating expenses, higher noncash stock compensation, a planned rise in cash OpEx for 2026 (~$35M to ~$50M), and timing/lumpiness risks around revenue and cash collections. On balance, the operational and commercial achievements, plus the legal settlement and capital raise, outweigh the near‑term expense increases and timing risks, leaving the company positioned for growth provided the planned commercial and medical investments ramp as expected.View all TSE:FRX earnings summariesFRX Stock 12 Month Forecast
Average Price Target
C$20.73
▲(129.32% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Options Prices
Currently, No data available
---